Zafer Pekkolay
Overview
Explore the profile of Zafer Pekkolay including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
133
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ciftci S, Yilmaz N, Selcukbiricik O, Hekimsoy Z, Gokcay Canpolat A, Topsakal S, et al.
Endocrine
. 2024 Sep;
86(3):1148-1155.
PMID: 39287756
Objective: To compare clinical and hormonal data, neuroendocrine neoplasia (NEN) localization, treatment, and survival outcomes in ectopic Cushing's syndrome (ECS) by sex. Methods: Eleven experienced centers from our country participated...
2.
Hacioglu A, Karaca Z, Uysal S, Ozkaya H, Kadioglu P, Selcukbiricik O, et al.
Eur J Endocrinol
. 2024 Aug;
191(3):312-322.
PMID: 39186535
Objective: Primary hypophysitis might be challenging to diagnose, and there is a lack of evidence regarding optimal treatment strategies due to rarity of the disease. We aim to investigate the...
3.
Zuhur S, Ozturk B, Keskin U, Uysal S, Hacioglu A, Avci U, et al.
Endocrine
. 2024 Apr;
85(3):1300-1309.
PMID: 38570387
Purpose: Despite several factors that may have been associated with poor disease-free survival (DFS) in patients with medullary thyroid carcinoma (MTC), only a few studies have evaluated the prognostic factors...
4.
5.
Batman A, Yazici D, Dikbas O, Agbaht K, Saygili E, Demirci I, et al.
J Clin Endocrinol Metab
. 2023 May;
108(10):e1013-e1026.
PMID: 37186260
Context: The aims of the study are to compare characteristics of subacute thyroiditis (SAT) related to different etiologies, and to identify predictors of recurrence of SAT and incident hypothyroidism. Methods:...
6.
Pekkolay Z, Yildirim D, Tuzcu S, Tasdemir B, Tuzcu A
J Clin Densitom
. 2023 Mar;
26(2):101363.
PMID: 37002004
Purpose: Sclerostin reduces bone formation by inhibiting the Wnt signaling pathway in bone tissue. This study evaluated the serum sclerostin level in non-functioning pituitary adenoma (NFPA) patients and analyzed its...
7.
Yildirim Simsir I, Tuysuz B, Ozbek M, Tanrikulu S, Celik Guler M, Karhan A, et al.
Diabetes Obes Metab
. 2023 Mar;
25(7):1950-1963.
PMID: 36946378
Aim: To describe the Turkish generalized lipodystrophy (GL) cohort with the frequency of each complication and the death rate during the period of the follow-up. Methods: This study reports on...
8.
Sabancilar I, Unsal V, Demir F, Toprak G, Pekkolay Z
Folia Med (Plovdiv)
. 2023 Mar;
65(1):46-52.
PMID: 36855973
Introduction: Sclerostin is a glycoprotein known as a negative regulator of bone formation, predominantly expressed by mature osteocytes. There is no causative evidence information on the role of sclerostin in...
9.
Besci O, Firat S, Ozen S, Cetinkaya S, Akin L, Kor Y, et al.
J Clin Endocrinol Metab
. 2023 Feb;
108(9):2371-2388.
PMID: 36825860
Context: Homozygous leptin (LEP) and leptin receptor (LEPR) variants lead to childhood-onset obesity. Objective: To present new cases with LEP and LEPR deficiency, report the long-term follow-up of previously described...
10.
Yavuz D, Yazan C, Hekimsoy Z, Aydin K, Gokkaya N, Ersoy C, et al.
Clin Endocrinol (Oxf)
. 2022 May;
97(6):833-840.
PMID: 35639050
Objective: Thyroid-stimulating hormone (TSH) suppression treatment can induce signs and symptoms of hyperthyroidism and hypothyroidism due to inappropriate treatment or poor compliance to the treatment. The current study aimed to...